Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Botanicals’ safety

This article was originally published in The Tan Sheet

Executive Summary

Botanical dietary supplements with a safe history may not require the same level of toxicity testing as synthetic pharmaceutical drugs, according to research published in the February American Journal of Clinical Nutrition. Misidentification, production errors, contamination or poor manufacturing processes are associated with most incidences of toxicity in supplements, according to Richard B. van Breemen at the University of Illinois-Chicago National Institutes of Health Center for Botanical Dietary Supplements Research. Additionally, botanical-drug interactions can be a source of toxicity, including formation of electrophilic metabolites, allergic reactions, botanical-induced autoimmune reactions, or specific systemic or organ-specific reactions, the researchers say. However, most toxicity can be prevented by sound agricultural and manufacturing practices and by applying existing toxicity tests similar to those used in drug development or new toxicity assays under development based on proteomics, genomics or metabolomics, van Breeman et al. say...

You may also be interested in...



QUOTED. 18 June 2021. Harith Rajagopalan.

Fractyl Health closed a $100m financing round to support ongoing development of duodenal mucosal resurfacing (DMR) technology that addresses root causes of type 2 diabetes. CEO Harith Rajagopalan spoke of his hopes for the technology.

Will COVID Finally Help US FDA And Sponsors Overcome Their ‘Angst’ On Innovative Trial Designs?

The ‘sea change’ inside White Oak should be seen as very encouraging for sponsors, FDA official says.

Domestic In-Person Inspection Work Could Be Back To Normal This Summer, Woodcock Says

Foreign facility visits may take longer to reach usual levels because of the ongoing coronavirus outbreaks in other countries.

Topics

UsernamePublicRestriction

Register

PS101335

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel